Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BetterLife Pharma ( (TSE:BETR) ) is now available.
BetterLife Pharma has appointed Dr. Steven Sangha to its Board of Directors, bringing over 25 years of experience in investment banking, business development, and asset management. Dr. Sangha, a major shareholder, believes in the potential of BETR-001 to disrupt the treatment of depression, anxiety, PTSD, and addiction. His expertise is expected to aid BetterLife in advancing its non-hallucinogenic compounds for psychiatric and neurological disorders, potentially impacting the company’s operations and industry positioning.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. Its primary products include BETR-001, a non-hallucinogenic LSD derivative, and BETR-002, based on honokiol, both in preclinical and IND-enabling studies.
YTD Price Performance: -22.67%
Average Trading Volume: 17,651
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.15M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.